Article | Population | Methotrexate | Method | Pharmacokinetic results | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
First author, year, journal | N | From | Age (y)† | CD (%) | Active disease (%) | Oral (%) | Dose (mg/wk) | Co-therapy (%) | Study dsesign | Method of MTX-PG measurement | |
Morrow, 2021, Pharmaceuticals17 & Shakhnovich, 2019, [A] Gastroenterology25 | 21 | USA | 5–21 | 90 | 48 | 86 | 5–25† | IFX (100) | Cross-sectional | HPLC–MS/MS of MTX-PG1-6 | Relationship of dose and MTX-PGtotal (ρ = 0.56) and MTX-PG(3–5) (ρ = 0.51) No relationship of IFX concentration and MTX-PGtotal or MTX-PG3-5 No relationship of route of administration and MTX-PG concentration§ |
Fischer, 2017, Clinical Pharmacology and Drug Development18 & Shivi, 2014, [A] Inflammatory bowel disease26 | 12 | USA | 30–68 | 100 | 42 | 17 | 25; at least 12 weeks | Steroid (25) | Cross-sectional | HPLC–MS/MS of MTX-PG1-5 | Interpatient variation of 28-fold for MTX-PGtotal |
Fong, 2014, [A] Journal of Crohn’s and Colitis19 | 21 | UK | 22–59 | 76 | 57 | 90 | 17 ± 1ǂ | IFX (57) ADA (14) | Retrospective cohort | HPLC of MTX-PG1-5 | A linear relationship between dose of MTX and PG1–5 was observed (ρ = n/a) |
Brooks, 2007, Therapeutic Drug Monitoring20 | 18 | NZ | 24–80 | 72 | 37 | 78 | 15–25†; at least 12 weeks | Steroid (39) | Cross-sectional | HPLC –UV (day 0, 14 and 28) of MTX-PG1-5 | Dose-dependent increase of MTX-PG4 and MTX-PG(4,5) and MTX-PG (3,4,5) (ρ = n/a) No relationship between MTX-PGn and eGFR |
Egan, 1999, Alimentary Pharmacology and Therapeutics21 | 30 | USA | 21–71 | 53 | n/a | 0 | 15 (60%) 25 (40%) | Steroid (100) | Prospective cohort of 16 weeks | Competitive protein binding assay of MTX-PGtotal | Significant increase of MTX-PGtotal after dose escalation |